KR20100055453A - 홍반을 치료하기 위한 개선된 브리모니딘 조성물 - Google Patents

홍반을 치료하기 위한 개선된 브리모니딘 조성물 Download PDF

Info

Publication number
KR20100055453A
KR20100055453A KR1020107005023A KR20107005023A KR20100055453A KR 20100055453 A KR20100055453 A KR 20100055453A KR 1020107005023 A KR1020107005023 A KR 1020107005023A KR 20107005023 A KR20107005023 A KR 20107005023A KR 20100055453 A KR20100055453 A KR 20100055453A
Authority
KR
South Korea
Prior art keywords
composition
gel
skin
erythema
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107005023A
Other languages
English (en)
Korean (ko)
Inventor
클라우스 테오발트
크리스토퍼 브이. 포알라
Original Assignee
갈더마 라보라토리즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈더마 라보라토리즈 인코포레이티드 filed Critical 갈더마 라보라토리즈 인코포레이티드
Publication of KR20100055453A publication Critical patent/KR20100055453A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107005023A 2007-08-31 2008-08-29 홍반을 치료하기 위한 개선된 브리모니딘 조성물 Ceased KR20100055453A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96719107P 2007-08-31 2007-08-31
US60/967,191 2007-08-31

Publications (1)

Publication Number Publication Date
KR20100055453A true KR20100055453A (ko) 2010-05-26

Family

ID=40407909

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107005023A Ceased KR20100055453A (ko) 2007-08-31 2008-08-29 홍반을 치료하기 위한 개선된 브리모니딘 조성물

Country Status (12)

Country Link
US (3) US20090061020A1 (enExample)
EP (1) EP2200617A4 (enExample)
JP (1) JP2010537988A (enExample)
KR (1) KR20100055453A (enExample)
CN (2) CN102552112A (enExample)
AR (1) AR068816A1 (enExample)
AU (1) AU2008296948A1 (enExample)
BR (1) BRPI0816097A2 (enExample)
CA (1) CA2698680A1 (enExample)
MX (1) MX2010002392A (enExample)
NO (1) NO20100301L (enExample)
WO (1) WO2009032223A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
CN104324378A (zh) * 2009-05-29 2015-02-04 盖尔德马研究及发展公司 用于减少注射引起的皮肤反应的肾上腺素能受体激动剂和填充剂的可注射组合物
KR20120125230A (ko) * 2009-10-26 2012-11-14 갈더마파마 에스.아. 급성 홍반 치료 또는 예방 방법
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
BR112012024289A2 (pt) * 2010-03-26 2017-07-18 Galderma Res & Dev "método para fornecer um tratamento seguro e efetivo do eritema e composição de gel tópica"
RU2535008C2 (ru) * 2010-03-26 2014-12-10 Галдерма Ресерч Энд Девелопмент Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
JP2013540142A (ja) * 2010-10-21 2013-10-31 ガルデルマ・ソシエテ・アノニム 局所ゲル組成物
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
BR112013009578B1 (pt) * 2010-10-21 2020-10-20 Galderma S.A. composição tópica em gel e uso de uma composição tópica em gel
KR20190114010A (ko) 2011-02-15 2019-10-08 어클라리스 쎄라퓨틱스, 인코포레이티드 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들
BR112014009210A2 (pt) 2011-10-19 2017-04-18 Galderma Sa método para a redução da vermelhidão facial cutânea
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
FR3000398A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
FR3015288B1 (fr) 2013-12-19 2016-02-12 Galderma Res & Dev Utilsation du naratriptan dans le traitement de la rosacee
AU2015274532B2 (en) 2014-06-11 2020-06-11 Epi Health, Llc Stabilized oxymetazoline formulations and their uses
EP3651767A1 (en) 2017-07-14 2020-05-20 Galderma Research & Development Methods and compositions for reducing side effects in chemotherapeutic treatments
WO2020222188A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
GB8827968D0 (en) * 1988-11-30 1989-01-05 Boots Co Plc Sunscreen compositions
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US6410045B1 (en) * 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050276765A1 (en) * 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
KR20100099191A (ko) * 2007-12-21 2010-09-10 갈더마 라보라토리즈 인코포레이티드 수술전 처리

Also Published As

Publication number Publication date
MX2010002392A (es) 2010-07-28
BRPI0816097A2 (pt) 2016-11-01
NO20100301L (no) 2010-03-25
AR068816A1 (es) 2009-12-09
JP2010537988A (ja) 2010-12-09
CA2698680A1 (en) 2009-03-12
AU2008296948A1 (en) 2009-03-12
CN101808645A (zh) 2010-08-18
US20120282346A1 (en) 2012-11-08
WO2009032223A1 (en) 2009-03-12
US20090061020A1 (en) 2009-03-05
EP2200617A1 (en) 2010-06-30
CN102552112A (zh) 2012-07-11
EP2200617A4 (en) 2011-01-12
US20120040016A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
KR20100055453A (ko) 홍반을 치료하기 위한 개선된 브리모니딘 조성물
RU2587041C2 (ru) Способ предотвращения или лечения опухоли кожи
ES2376172T5 (es) Compuestos, formulaciones y métodos para tratar o prevenir la rosácea
EP2481412B1 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
JP5747391B2 (ja) 紅斑の安全かつ有効な治療のための改善された方法および組成物
JP2010537988A5 (enExample)
US9504661B2 (en) Dapsone to treat rosacea
KR20100099191A (ko) 수술전 처리
JP2016525553A (ja) 皮膚肥厚の治療法
KR20140091544A (ko) 모세혈관종 치료방법
JP2014530846A (ja) ホスホジエステラーゼ５型阻害薬の全身使用に伴う顔面潮紅の軽減方法
EP2595616A2 (en) Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
US20190021995A1 (en) Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses
HK1175698A1 (en) Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis
HK1175698B (en) Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis
HK1180208B (en) Compositions comprising brimonidine for the treatment of erythema
HK1180208A (en) Compositions comprising brimonidine for the treatment of erythema

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100305

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130723

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150102

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150701

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150102

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I